Alcon Shareholders Approve Merger with Novartis
Alcon, Inc. (NYSE:ACL) announced that its shareholders approved the merger of Alcon into Novartis AG at its Annual General Meeting of Shareholders. Under the terms of the merger, Alcon shareholders will receive 2.9228 Novartis shares or American Depositary Shares plus a cash payment of $8.20 for each Alcon share. Completion of the merger is subject to approval by the Novartis shareholders, which vote will take place on April 8, 2011. Following completion of the merger, Alcon will terminate its listing on the New York Stock Exchange.
The Alcon shareholders also re-elected Dr. Daniel Vasella, Cary Rayment, Thomas Plaskett, Dr. Enrico Vanni, and Norman Walker to the board of directors for the period between the Annual General Meeting of Shareholders and the completion of the merger. Shareholders also voted to grant a discharge to the current and former members of the board of directors, approved the 2010 business report and approved KPMG as auditor.
Company Description
Alcon, Inc. is the world’s leading eye care company, with sales of approximately $7.2 billion in 2010. Alcon, which has been dedicated to the ophthalmic industry for 65 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon operates in 75 countries and sells products in 180 markets. For more information on Alcon, Inc., visit the Company’s web site at www.alcon.com .
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements principally relate to statements regarding the expectations of our management with respect to the future performance of various aspects of our business. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. Words such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "hope," "intend," "estimate," "project," "predict," "potential" and similar expressions are intended to identify forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties and are not intended to give any assurance as to future results. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that might cause future results to differ include, but are not limited to, the following: the development of commercially viable products may take longer and cost more than expected; changes in reimbursement procedures by third-party payers may affect our sales and profits; a weakening economy could affect demand for our products; competition may lead to worse than expected financial condition and results of operations; currency exchange rate fluctuations may negatively affect our financial condition and results of operations; pending or future litigation may negatively impact our financial condition and results of operations; litigation settlements may adversely impact our financial condition; the occurrence of excessive property and casualty, general liability or business interruption losses, for which we are self-insured, may adversely impact our financial condition; product recalls or withdrawals may negatively impact our financial condition or results of operations; government regulation or legislation may negatively impact our financial condition or results of operations; changes in tax laws or regulations in the jurisdictions in which we and our subsidiaries are subject to taxation may adversely impact our financial performance; supply and manufacturing disruptions could negatively impact our financial condition or results of operations. You should read this press release with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Contact:
Alcon, Inc.
Doug MacHatton,
817-551-8974
Vice
President, Treasury and Investor and Public Relations
doug.machatton@alconlabs.com
www.alcon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 202524.7.2025 23:02:00 CEST | Press release
- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations Incyte (Nasdaq:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. “We're looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data undersc
DNIB.com Reports Internet Has 371.7 Million Domain Name Registrations at the End of the Second Quarter of 202524.7.2025 23:01:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the second quarter of 2025 closed with 371.7 million domain name registrations across all top-level domains (TLDs), an increase of 3.3 million domain name registrations, or 0.9% compared to the first quarter of 2025. Domain name registrations also increased by 9.3 million, or 2.6%, year over year. The .com and .net TLDs had a combined total of 170.5 million domain name registrations in the domain name base at the end of the second quarter of 2025, an increase of 0.7 million domain name registrations, or 0.4% compared to the first quarter of 2025. The .com and .net TLDs had a combined decrease of 0.1 million domain name registrations, or 0.1%, year over year. As of June 30, 2025, the .com domain name base totaled 157.9 million domain name registrations and the .net
SES and the Luxembourg Government to Develop and Launch New Defence Satellite for GovSat24.7.2025 18:55:00 CEST | Press release
GovSat-2 is aimed at meeting growing demand for highly secure, flexible MILSATCOM services SES and the Luxembourg Government today announced their plan for development of a second satellite for GovSat (LuxGovSat S.A.), the public-private partnership and 50/50 joint venture between SES and the Luxembourg Government that provides secure, reliable and accessible satellite communication services for governments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724379713/en/ GovSat-2. Copyright: Thales Alenia Space GovSat-2 will be positioned over the European satellite arc. It will join GovSat-1 in augmenting reliable connectivity services for government customers over the region. The satellite will be built by Thales Alenia Space on its Spacebus 4000B2 platform. Since launching in 2018, the joint venture’s first defence satellite, GovSat-1, operated by GovSat from a secure missions operations centre in Luxembourg, has supporte
Infobip Named a Leader in 2025 Gartner® Magic Quadrant™ for Communications Platform-as-a-Service for the Third Consecutive Year24.7.2025 18:21:00 CEST | Press release
Infobip positioned furthest in Completeness of Vision Global communications platformInfobiphas once again been named a Leader in the 2025 Gartner Magic Quadrant for Communications Platform-as-a-Service (CPaaS)1. This year the company is placed furthest in Completeness of Vision. Infobip views this third consecutive recognition as acknowledging its status as a global CPaaS powerhouse. Magic Quadrant2 reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables customers to get the most from market analysis in alignment with their unique business and technology needs. As a Leader, Infobip is recognized for both its Ability to Execute and its Completeness of Vision. Infobip powers conversations for some of the
Andersen Consulting fremmer digitale transformationsmuligheder med eksponentielle digitale løsninger24.7.2025 17:43:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at opbygge sin digitale konsulentplatform gennem et samarbejde med Exponential Digital Solutions (10xDS), et firma der specialiserer sig i AI-drevet transformation og nye teknologier. 10xDS blev stiftet i 2016 af adminstrerende direktør Binu Koshy og leverer next generation-løsninger inden for automatisering, analyse, kunstig intelligens, cybersikkerhed og udvikling af digitale produkter. Virksomhedens tværfaglige tilgang kombinerer teknisk ekspertise med strategisk indsigt og støtter kunderne i deres implementering og skalering af next generation-løsninger. Med international erfaring inden for forskellige brancher arbejder 10xDS på at løse operationelle ineffektiviteter og skabe ny værdi gennem digital innovation. "Hos 10xDS har vi opbygget en organisation, der er baseret på innovation og troen på, at AI og nye teknologier kan føre til betydeligt bedre forretningsresultater," siger Binu. "Dette samarbejde understøtter vores mission om at skalere tran
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom